Abbott Laboratories has issued a medical device correction for approximately 3 million FreeStyle Libre 3 and Libre 3 Plus glucose sensors in the U.S. after identifying a production line issue that may result in incorrect low glucose readings. This could lead to incorrect treatment decisions for people with diabetes, posing serious health risks. Globally, Abbott has received reports of 736 severe adverse events and seven deaths potentially linked to this issue, though no deaths have been reported in the U.S. The company has resolved the production issue, continues to supply sensors, and does not anticipate significant supply disruptions. Consumers are advised to check if their sensors are affected at https://www.FreeStyleCheck.com and to discontinue use of impacted sensors immediately. Other Abbott Libre products and devices are not affected.